Previously, FACILITATE, a real-world, prospective, multicenter, European study, evaluated the performance and analytical turnaround time of the IdyllaTM EGFR mutation test compared with local reference methods in non-small-cell-lung-cancer patients, showing an overall percentage agreement of 97.7% and an analytical turnaround time within 1 week versus about 22 days using reference methods [13]. The gene discussed is EGFR; the disease is small cell lung carcinoma.